Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial)

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 1035-1037

  Prandoni, Paolo ^a   Taher, Ali ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Dabigatran; Venous thromboembolism; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME METABOLISM; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; LIVER FUNCTION TEST; NOTE; PATIENT COMPLIANCE; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; EUROPE; HEMORRHAGE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NORTH AMERICA; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 77949882057     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003674397     Document Type: Note

References (9)

1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352
2. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:160-198S
3. Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008;68:1699-1709
4. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956
5. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151
7. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-331
8. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689
9. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721